Related Experiment Videos
Graft-versus-host reactions and bone-marrow transplantation
1St Jude Children's Research Hospital, Memphis, Tennessee.
Current Opinion in Immunology
|October 1, 1991
Summary
Bone marrow transplants are advancing with unrelated donors and growth factors improving recovery. New research suggests separating anti-leukemic effects from graft-versus-host disease is possible.
Area of Science:
- Hematology
- Immunology
- Transplantation Medicine
Background:
- Bone marrow transplantation (BMT) is a critical therapy for hematologic malignancies and other diseases.
- Advances in donor selection and supportive care have improved BMT outcomes.
- Graft-versus-host disease (GVHD) remains a significant complication limiting BMT efficacy.
Purpose of the Study:
- To review recent rapid advancements in bone marrow transplantation.
- To highlight progress in unrelated donor and HLA-mismatched transplants.
- To discuss the potential for separating anti-leukemic effects from GVHD.
Main Methods:
- Review of recent clinical trials and observational studies in bone marrow transplantation.
- Analysis of data on recombinant hemopoietic growth factor efficacy.
- Synthesis of findings related to allograft mechanisms in leukemia treatment and GVHD.
Main Results:
- Successful performance of increased bone marrow transplants using matched unrelated donors or HLA-mismatched family members.
- Recombinant hemopoietic growth factors demonstrated acceleration of hemopoietic recovery and reduction of post-transplant complications.
- Emerging data suggest potential mechanisms to dissociate the anti-leukemic activity of allografts from GVHD induction.
Conclusions:
- Bone marrow transplantation is rapidly evolving with expanded donor options and improved supportive care.
- Recombinant hemopoietic growth factors enhance recovery and reduce complications post-transplant.
- Future research may enable strategies to harness the anti-leukemic benefits of BMT while mitigating GVHD.